Structural Insights into Emerging Inhibitors Targeting EGFR Mutations

Time: 12:00 pm
day: Day Two


  • The structure of lazertinib allows for enhanced potency and mutant selectivity against EGFR T790M
  • Next generation mutant EGFR C797S inhibitors bind the kinase domain through H-bonding with conserved catalytic residues
  • Spanning ATP-allosteric EGFR inhibitors can be developed exhibiting unique kinase domain binding and mutant selectivity